Burning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) released its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, Zacks reports. Burning Rock Biotech had a negative net margin of 26.04% and a negative return on equity of 23.61%.

Burning Rock Biotech Price Performance

NASDAQ BNR traded up $1.97 during trading on Thursday, hitting $18.00. The company’s stock had a trading volume of 26,763 shares, compared to its average volume of 31,119. Burning Rock Biotech has a fifty-two week low of $2.18 and a fifty-two week high of $18.51. The company has a market cap of $193.68 million, a PE ratio of -9.47 and a beta of 1.11. The business’s 50 day simple moving average is $10.31 and its 200-day simple moving average is $6.92.

Wall Street Analysts Forecast Growth

BNR has been the subject of a number of analyst reports. Wall Street Zen upgraded Burning Rock Biotech to a “buy” rating in a research note on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.